Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fish and Richardson
Boehringer Ingelheim
Johnson and Johnson
McKesson
Queensland Health
Daiichi Sankyo
Citi
Accenture

Generated: January 22, 2019

DrugPatentWatch Database Preview

JANSSEN Company Profile

« Back to Dashboard

Summary for JANSSEN

Drugs and US Patents for JANSSEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ➤ Sign Up ➤ Sign Up
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-004 Dec 18, 2008 RX Yes No 7,700,645*PED ➤ Sign Up Y ➤ Sign Up
Janssen Prods PREZISTA darunavir ethanolate SUSPENSION;ORAL 202895-001 Dec 16, 2011 RX Yes Yes 8,597,876*PED ➤ Sign Up Y ➤ Sign Up
Janssen Prods SYMTUZA cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes 8,148,374 ➤ Sign Up Y Y ➤ Sign Up
Janssen Res And Dev FLEXERIL cyclobenzaprine hydrochloride TABLET;ORAL 017821-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Janssen Pharms ORTHO-NOVUM 7/7/7-28 ethinyl estradiol; norethindrone TABLET;ORAL-28 018985-002 Apr 4, 1984 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for JANSSEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms DURAGESIC-25 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 019813-004 Aug 7, 1990 4,588,580*PED ➤ Sign Up
Janssen Pharms ORTHO-NOVUM 7/7/7-28 ethinyl estradiol; norethindrone TABLET;ORAL-28 018985-002 Apr 4, 1984 4,628,051 ➤ Sign Up
Janssen Pharms RISPERDAL CONSTA risperidone INJECTABLE;INTRAMUSCULAR 021346-003 Oct 29, 2003 5,792,477*PED ➤ Sign Up
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-002 Aug 1, 2000 5,082,668*PED ➤ Sign Up
Janssen Pharms RAZADYNE galantamine hydrobromide TABLET;ORAL 021169-002 Feb 28, 2001 4,663,318 ➤ Sign Up
Janssen Pharms TERAZOL 7 terconazole CREAM;VAGINAL 019579-001 Dec 31, 1987 4,358,449 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for JANSSEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 4 mg, 8 mg and 12 mg ➤ Subscribe 2005-02-28
➤ Subscribe Orally Disintegrating Tablets 3 mg and 4 mg ➤ Subscribe 2005-03-23
➤ Subscribe Extended-release Tablets 18 mg, 27 mg, 36 mg and 54 mg ➤ Subscribe 2005-07-19
➤ Subscribe Tablets 6.25 mg and 12.5 mg ➤ Subscribe 2005-12-08
➤ Subscribe Tablets 500 mg ➤ Subscribe 2017-08-23
➤ Subscribe Tablets 100 mg and 300 mg ➤ Subscribe 2017-03-29
➤ Subscribe Extended-release Capsules 16 mg and 24 mg ➤ Subscribe 2006-03-11
➤ Subscribe Tablets 800 mg ➤ Subscribe 2013-05-14
➤ Subscribe Tablets 25 mg, 100 mg and 200 mg ➤ Subscribe 2001-12-26
➤ Subscribe Capsules 15 mg and 25 mg ➤ Subscribe 2005-09-07
➤ Subscribe Oral Solution 25 mg/mL ➤ Subscribe 2009-07-30
➤ Subscribe Orally Disintegrating Tablets 0.25 mg ➤ Subscribe 2005-04-11
➤ Subscribe Extended-release Injectable Suspension 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL ➤ Subscribe 2017-11-21
➤ Subscribe Extended-release Tablets 18 mg*, 27 mg, 36 mg and 54 mg ➤ Subscribe 2005-07-19
➤ Subscribe Tablets 250 mg ➤ Subscribe 2015-04-28
➤ Subscribe Tablets 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg ➤ Subscribe 2017-03-29
➤ Subscribe Extended-release Capsules 8 mg ➤ Subscribe 2006-03-02
➤ Subscribe Tablets 10 mg, 15 mg, and 20 mg ➤ Subscribe 2015-07-01
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2013-05-03
➤ Subscribe Tablets 50 mg ➤ Subscribe 2005-09-08
➤ Subscribe Transdermal System 0.15 mg/0.02 mg per 24 hours ➤ Subscribe 2007-03-22

Supplementary Protection Certificates for JANSSEN Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
49/2008 Austria ➤ Sign Up PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
33/2007 Austria ➤ Sign Up PRODUCT NAME: DARUNAVIR UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE
C0060 France ➤ Sign Up PRODUCT NAME: BEDAQUILINE OU UN DE SES SELS D'ADDITION D'ACIDE OU DE BASE PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE FUMARATE DE BEDAQUILINE; REGISTRATION NO/DATE: EU/1/13/901 20140307
2004 Austria ➤ Sign Up PRODUCT NAME: EMTRICITABIN; NAT. REGISTRATION NO/DATE: EU/1/03/261/001- EU/1/03/261/003 20031024; FIRST REGISTRATION: EU EU/1/03/261/003
11/021 Ireland ➤ Sign Up PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
00521 Netherlands ➤ Sign Up PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Covington
Cipla
Harvard Business School
Moodys
Baxter
McKinsey
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.